Trevi Therapeutics Strategy and Business Model

Executive Overview

Trevi Therapeutics is a New Haven, Connecticut-based clinical-stage biopharmaceutical company developing Haduvio, an investigational oral extended-release nalbuphine formulation, for serious conditions driven by chronic cough or pruritus. Founded in 2011, Trevi operates in the biotechnology and specialty-pharma sector, but its strategy is narrower than that of a typical platform biotech: it is trying to create value by advancing one lead asset across selected neurologically mediated indications with high unmet need. As of 2024 public disclosures, the company’s main priorities were chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), with prurigo nodularis remaining part of the broader Haduvio story.

That focus matters commercially. If Haduvio succeeds, Trevi would be addressing specialist markets served by pulmonologists, interstitial lung disease centers, cough specialists, and potentially dermatologists rather than a mass primary-care base. Trevi’s operating footprint is lean and largely outsourced, with clinical, regulatory, and manufacturing activities managed through external partners rather than a large internal infrastructure. Because it is still a clinical-stage company, Trevi remained pre-revenue in FY2023, so the business today is driven by clinical milestones, regulatory progress, and capital management rather than current product sales.

Trevi Therapeutics at a Glance

Logo
Common name	Trevi Therapeutics
Full legal name	Trevi Therapeutics, Inc.
Headquarters	New Haven, Connecticut, United States
Ownership	Public company; Nasdaq-listed, with no controlling shareholder typically disclosed in annual filings
Ticker	TRVI
Exchange	NASDAQ
Market Cap	$2.50B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2011; listed on Nasdaq in 2019; initially emphasized chronic pruritus and prurigo nodularis; later increased focus on chronic cough after encouraging IPF cough data
Industry or industries	Biotechnology; clinical-stage biopharmaceuticals; specialty therapeutics
Key products or services	Haduvio (investigational oral nalbuphine extended-release); drug development in chronic cough in IPF, refractory chronic cough, and prurigo nodularis
Geographic footprint	U.S.-based corporate footprint with outsourced clinical-development and manufacturing network; trial activity in the United States and selected external sites
Business segments as officially reported	One operating and reportable segment
Company website	https://www.trevitherapeutics.com/

1. What Is the Strategy of Trevi Therapeutics?

Based on Trevi Therapeutics’ public filings and management commentary through 2024, the company’s strategy is to create a focused specialty-biopharma franchise around Haduvio by targeting indications with high unmet need, measurable symptom burden, and a specialist prescriber base. In Playing to Win terms, Trevi is not trying to be a broad discovery platform. It is making a narrower bet that one differentiated mechanism can support multiple value-creating indications if the clinical data are strong enough.

1. 1a. What is the winning aspiration of Trevi Therapeutics?

   Trevi’s practical winning aspiration is to get Haduvio approved and commercialized in serious chronic cough and pruritus indications where current treatment options are limited or unsatisfactory. As a clinical-stage biotech, the company does not present “winning” primarily as current revenue scale. Instead, public materials frame success around generating compelling clinical data, progressing through regulatory pathways, and becoming a meaningful specialty-therapy company in high-need symptom indications. The closest thing to a near-term scorecard is advancement of Haduvio through late-stage-enabling development in chronic cough, particularly IPF-related cough and RCC.

2. 1b. Where does Trevi Therapeutics play?

   Trevi plays in specialty biopharma, specifically in neurologically mediated symptom conditions where patients suffer substantial daily burden and where specialist physicians manage care. As of 2024, the company’s disclosed target indications centered on chronic cough in idiopathic pulmonary fibrosis, refractory chronic cough, and prurigo nodularis. That is a deliberate narrowing of the field: Trevi is not competing across broad respiratory or dermatology markets, but in subsets where an effective therapy could justify focused development and, if approved, a targeted commercial model.

3. 1c. How does Trevi Therapeutics plan to win?

   Trevi appears to plan to win through differentiation on mechanism, indication selection, and operating focus. Haduvio combines kappa opioid receptor agonist activity with mu opioid receptor antagonist activity, which Trevi believes can address chronic cough and pruritus through central and peripheral pathways. That gives it a different profile from the better-known P2X3 antagonists in chronic cough. The company also benefits from building around a single lead asset rather than managing a sprawling pipeline, which can sharpen capital allocation and clinical execution. If Trevi produces strong efficacy and tolerability data, the commercial model could also be efficient: cough in IPF and RCC are specialist markets that do not require a massive primary-care sales force.

4. 1d. What capabilities must Trevi Therapeutics have in place?

   Trevi needs several capabilities to make this strategy work. First is high-quality clinical-development execution in hard-to-study symptom indications, including trial design, endpoint selection, patient recruitment, and interpretation of cough and itch data. Second is regulatory capability, because symptom indications can require careful alignment with the U.S. Food and Drug Administration on endpoints, safety, and approvability. Third is chemistry, manufacturing, and controls capability for an extended-release oral product. Fourth is specialist-market insight in pulmonology and dermatology. Finally, because Trevi is pre-commercial, capital-raising and cash management are not support functions; they are core strategic capabilities.

5. 1e. What management systems does Trevi Therapeutics require?

   Trevi needs disciplined stage-gate management systems. In practice, that means milestone-based portfolio reviews, tight vendor oversight for contract research and manufacturing partners, safety and pharmacovigilance processes, cash-runway monitoring, and board-level governance around development priorities. Because the company is heavily outsourced, program management and quality systems matter disproportionately. A small biotech with one main asset can lose time quickly if enrollment slips, manufacturing changes are not controlled, or external partners are not managed tightly.

2. What Are the Current Strategic Initiatives of Trevi Therapeutics?

As of 2024 public disclosures, Trevi Therapeutics’ current strategic initiatives were centered on converting Haduvio from a promising clinical asset into a program with registrational and commercial credibility.

Advance Haduvio in refractory chronic cough

A major current initiative is execution of the company’s clinical program in refractory chronic cough. This matters strategically because RCC is a large unmet-need indication relative to Trevi’s size and is a field where the competitive benchmark is increasingly set by P2X3 developers. Trevi’s goal is not only to show symptom improvement, but to demonstrate a benefit-risk profile that can stand out in a market that has already learned a great deal about efficacy and taste-related tolerability tradeoffs.

Build on proof-of-concept data in chronic cough in IPF

Trevi has also emphasized chronic cough in IPF, where it previously reported encouraging proof-of-concept data. Strategically, IPF cough can be attractive because the patient need is severe, the specialist prescriber base is concentrated, and there are limited approved cough-specific options. Trevi’s task is to turn early signal into a development path that is clinically persuasive and regulatorily actionable.

Preserve optionality around prurigo nodularis while prioritizing capital

Prurigo nodularis remains relevant to Trevi’s story because it helped establish Haduvio’s broader potential in chronic pruritus. However, public disclosures suggest that cough indications became a sharper near-term priority. The strategic issue is not whether prurigo disappears, but how much capital Trevi should commit to it relative to cough programs that may now offer better value inflection.

Strengthen development infrastructure around a single asset

Trevi’s strategy also requires continued work on regulatory interactions, manufacturing readiness, clinical supply, safety monitoring, and trial operations. For a company built around one lead program, these are not back-office details. They are the infrastructure that determines whether positive data can be translated into a registrational package and eventually a launch plan.

Maintain financial flexibility

Like most small clinical-stage biotechs, Trevi must align spending with milestones. Public commentary has consistently emphasized cash discipline, outsourced execution, and prioritization. That financial initiative is inseparable from the clinical one: preserving runway long enough to reach key readouts is itself a strategic objective.

3. What Is the Business Model of Trevi Therapeutics?

Trevi Therapeutics is best understood as a clinical-stage specialty-biopharma developer, not as a current commercial drug company. Its business model today and its intended business model after approval are different.

What customers actually buy

As of 2024, customers do not yet buy an approved Trevi product because Haduvio remains investigational. If Haduvio is approved, what customers would buy is a prescription specialty medicine aimed at reducing chronic cough or pruritus symptoms in tightly defined patient populations. The economic buyers would include payers and pharmacy benefit managers; the prescribing customers would be pulmonologists, interstitial lung disease specialists, cough specialists, and potentially dermatologists; the end users would be patients needing repeat therapy over time.

Recurring versus one-time revenue

The future commercial model would likely be repeat-prescription driven, not one-time. Chronic cough in IPF, RCC, and chronic pruritus are persistent conditions, so a successful therapy would tend to generate recurring refill demand rather than episodic procedure-like revenue. By contrast, the current pre-commercial model is funded primarily through equity capital and cash reserves rather than product sales.

How pricing power works

If approved, pricing power would come less from brand advertising and more from clinical differentiation in high-need specialist indications. In specialty pharma, pricing power usually depends on efficacy, tolerability, label scope, payer evidence, and the absence of close substitutes. Trevi’s ability to command attractive pricing would therefore hinge on how clearly Haduvio improves patient outcomes versus off-label alternatives and competing pipeline drugs.

Why the business mix matters

The mix matters because Trevi is highly concentrated. A company with one lead asset and a few indications can change its risk profile dramatically by shifting resources from one disease area to another. Cough-focused commercialization would likely require a pulmonology-heavy model, while prurigo nodularis would push Trevi toward dermatology. That affects market size, field-force design, payer strategy, and outside-partner needs.

What would drive gross margin, operating margin, and cash generation

At Trevi’s current stage, gross margin is not yet a meaningful operating concept because there is no product revenue. Operating losses are driven mainly by research and development spending and general and administrative expense. If commercialized, gross margin would likely be shaped by outsourced manufacturing cost, formulation economics, scale efficiency, and distribution support. Operating margin would then depend on how narrowly Trevi can target prescribers with a specialty field force rather than a broad primary-care infrastructure. Cash generation would eventually depend on prescription volumes, net pricing after rebates and gross-to-net deductions, and Trevi’s success in keeping overhead lean.

Revenue model

The intended revenue model is a prescription drug model with recurring utilization and specialty-commercial characteristics. It is not subscription-based, transaction-based, or equipment-based. In the pre-approval phase, however, Trevi’s practical revenue model is better described as milestone-driven value creation financed by investors rather than operating customers.

4. What Products and/or Services Does Trevi Therapeutics Sell?

Trevi Therapeutics does not yet sell an approved commercial product. Its value proposition is centered on one investigational therapy:

• Haduvio: an investigational oral extended-release formulation of nalbuphine. Trevi has positioned Haduvio as a treatment candidate for chronic cough in idiopathic pulmonary fibrosis, refractory chronic cough, and prurigo nodularis.

From a portfolio perspective, the most important “product lines” are really indication pathways for the same molecule:

• Chronic cough in IPF: strategically important because of concentrated specialist care and severe unmet need.
• Refractory chronic cough: potentially larger commercial opportunity, but also a more visible competitive battleground.
• Prurigo nodularis: an earlier area of emphasis that still demonstrates Haduvio’s broader symptom-control potential, even if Trevi has prioritized cough more heavily.

The clear revenue, profit, and strategic driver is Haduvio. There is no diversified multi-asset portfolio to offset program-specific risk. That makes every clinical update disproportionately important.

If one distinguishes between legacy and newer growth priorities, prurigo nodularis can be viewed as the earlier flagship development path, while chronic cough appears to have become the more central growth engine in public-facing strategy.

5. What Are the Key Competitors or Peers of Trevi Therapeutics?

Trevi Therapeutics has no approved product, so its competitive set is a mix of direct pipeline competitors, indirect disease-area peers, and therapeutic substitutes. Chronic cough is the most important battlefield, but prurigo nodularis and IPF also matter.

The competitive picture is therefore unusual: Trevi is competing not only against named drug developers, but also against the inertia of off-label care in specialist medicine.

6. What Is the Marketing Strategy of Trevi Therapeutics?

Trevi Therapeutics is still pre-commercial, so its current marketing strategy is better described as scientific and stakeholder communication rather than product promotion.

Current pre-launch marketing priorities

• Key opinion leader engagement in pulmonology, interstitial lung disease, cough medicine, and dermatology.
• Disease-state education around the burden of chronic cough in IPF and RCC, where treatment dissatisfaction remains high.
• Clinical-trial awareness and recruitment support, which can be important in specialist populations.
• Investor communication, which is a strategically important external-facing function for a public clinical-stage biotech.

What post-approval marketing would likely look like

If Haduvio is approved, Trevi would likely use a narrow specialty-marketing model rather than broad consumer advertising. The emphasis would probably be on field medical and field sales engagement with pulmonologists, ILD centers, cough specialists, and possibly dermatologists. That would make account-based specialist outreach more important than mass-market brand advertising.

Is marketing a major differentiator?

At Trevi’s current stage, marketing is a supporting capability, not the main differentiator. Clinical data, label scope, tolerability, and payer access will matter more than branding. If the product reaches market, however, disease awareness and specialist education could become quite important because chronic cough treatment pathways remain fragmented and many patients are still managed with off-label therapies.

7. What Are the Key Customer Segments of Trevi Therapeutics?

Because Trevi Therapeutics is pre-commercial, its true customer segments are still prospective rather than current. The most important end markets would be the following:

• Pulmonologists and interstitial lung disease specialists: critical for chronic cough in IPF, where patient management is concentrated in specialist practices and academic centers.
• Chronic cough specialists: this can include pulmonology, allergy, otolaryngology, and multidisciplinary cough clinics involved in refractory chronic cough.
• Dermatologists: relevant if prurigo nodularis remains or becomes a larger commercial focus again.
• Payers, pharmacy benefit managers, and specialty pharmacies: these are essential economic gatekeepers in any specialty-drug launch.
• Patients and caregivers: especially important in chronic symptom indications where quality of life and persistence on therapy drive long-term value.

Trevi is not broadly diversified by customer type. Its opportunity depends on a relatively small number of specialist prescriber groups and a focused set of disease areas. That concentration can be a strength if the drug works, because it supports a targeted commercial footprint. It is also a risk because there is little diversification if one indication disappoints.

8. What Is the Sales Model of Trevi Therapeutics?

Trevi Therapeutics does not yet have a commercial sales model in operation because it has no approved product. Its likely go-to-market model, if Haduvio is approved, would be a specialty-pharma sales model.

Likely U.S. sales approach

• Direct specialty sales force focused on a relatively concentrated call point of pulmonologists, ILD centers, and cough specialists.
• Field medical team to support scientific exchange, data dissemination, and specialist education.
• Market access capabilities to negotiate payer coverage and manage evidence requirements.
• Specialty pharmacy and patient support services to handle prescription onboarding, reimbursement, and adherence support.

Likely ex-U.S. approach

For a company of Trevi’s size, partnering outside the United States would be a logical path if Haduvio succeeds, especially in markets where building a direct infrastructure would be inefficient.

Why channel structure matters

A focused specialty-sales model would support closer physician relationships and tighter message control, but it also means growth depends heavily on execution in a narrow prescriber base. For consultants, that channel structure creates very specific needs: prescriber mapping, launch sequencing, payer planning, referral-network design, and specialty-pharmacy strategy.

9. In What Geographies Does Trevi Therapeutics Operate?

Trevi Therapeutics is primarily a U.S.-based company. Its headquarters are in New Haven, Connecticut, and public disclosures emphasize a lean corporate footprint rather than a broad international operating network.

From an operating standpoint, Trevi’s geography is best understood in three layers:

• Corporate base: the United States, where management, strategy, finance, and much of regulatory oversight sit.
• Clinical-development footprint: trial activity conducted through external investigators, contract research organizations, and specialized sites in the United States and selected other markets.
• Manufacturing footprint: outsourced rather than owned, with drug supply produced through third-party partners.

Trevi does not resemble a multinational pharmaceutical company with a large network of plants, regional headquarters, and country sales organizations. Its current footprint is concentrated. If Haduvio reaches commercialization, Trevi would likely prioritize the United States first and use partners or staged expansion outside the U.S.

10. Who Are the Owners of Trevi Therapeutics?

Trevi Therapeutics is a publicly traded company listed on Nasdaq under the ticker TRVI. As is typical for a small-cap biotech, ownership is generally a mix of institutional investors, specialist healthcare funds, index-related holders, and company insiders.

Based on the structure commonly disclosed in annual proxy materials, Trevi does not appear to have a controlling shareholder with majority ownership. That matters because strategic direction is shaped primarily by management and the board, under the scrutiny of public-market investors, rather than by a founder-family or private-equity sponsor.

Because beneficial ownership positions can change materially quarter to quarter, the most current large-holder information should be taken from Trevi’s latest proxy statement and recent Schedule 13D, 13G, and Form 13F filings.

11. How Is Trevi Therapeutics Organized?

Trevi Therapeutics is organized like a focused clinical-stage biotech rather than a diversified pharmaceutical company. Public reporting indicates one operating and reportable segment, which is consistent with the company’s concentration around Haduvio.

At a practical level, the company is organized around a small number of essential functions:

• Research and development, including clinical strategy and program leadership
• Regulatory, medical, and safety, including interactions with regulators and oversight of clinical evidence
• Chemistry, manufacturing, and controls, managed largely through external partners
• General and administrative, including finance, legal, investor relations, and public-company requirements

Trevi does not currently have the divisional complexity of a large pharma company. There are no major brand houses, broad regional business units, or separate commercial segments. Instead, the organization is built to make development decisions quickly around one principal asset and a small set of indications.

12. How Does Trevi Therapeutics Operate?

Trevi Therapeutics creates value by managing the end-to-end development of Haduvio. In day-to-day terms, that means it operates less like a laboratory-heavy discovery company and more like a clinical-development orchestrator.

Core operating activities

1. Program selection and trial design: deciding which indications to pursue, how to sequence them, and what endpoints best demonstrate clinical value.
2. Clinical execution: working with investigators and contract research organizations to recruit patients, run studies, collect data, and maintain compliance.
3. Drug supply management: coordinating production of clinical material through third-party manufacturers and ensuring quality and continuity.
4. Regulatory management: interacting with the U.S. Food and Drug Administration and other regulators on trial design, safety, and eventual approval pathways.
5. Capital and governance management: raising capital, pacing spend, and communicating with investors.

Operational complexities

Trevi’s main operational challenges are not factory utilization or global distribution density. They are patient recruitment in specialist populations, endpoint rigor in symptom-driven diseases, vendor coordination, and single-asset concentration risk. In chronic cough, measurement quality matters: demonstrating symptom benefit can require robust objective and patient-reported evidence. In a small biotech, delays in any one of those areas can materially affect the whole company.

13. What Are the Growth Opportunities for Trevi Therapeutics?

Trevi Therapeutics’ growth opportunities are substantial if Haduvio works, but they are highly contingent because the company remains clinical-stage.

Most plausible growth opportunities

• Winning approval in refractory chronic cough: this could open a large specialist market and establish Haduvio as more than a niche rare-disease therapy.
• Commercializing in chronic cough in IPF: IPF cough appears smaller in absolute patient count, but strategically attractive because the unmet need is severe and the prescriber base is concentrated.
• Expanding into additional cough phenotypes: if mechanism and tolerability support it, Trevi could potentially pursue adjacent chronic-cough populations beyond the first approved label.
• Reactivating or reprioritizing pruritus indications: prurigo nodularis and related chronic itch disorders remain an optional source of pipeline expansion.
• Partnerships outside the United States: ex-U.S. licensing could provide capital, reduce infrastructure requirements, and expand geographic reach.
• Lifecycle management: a successful specialty drug can create follow-on opportunities in dosing, sequencing, evidence generation, and label extension.

Management-stated priorities versus external synthesis

Management has publicly emphasized advancing Haduvio in chronic cough and building on existing clinical data. A reasonable external synthesis is that Trevi’s biggest opportunity is not simply getting one approval, but proving that Haduvio can become a multi-indication specialty franchise.

Main constraints

• Clinical-development risk
• Regulatory uncertainty in symptom indications
• Competition from P2X3 programs and low-cost off-label care
• Capital requirements before commercialization
• Single-asset concentration

Those constraints are typical for small biotech, but they are sharper at Trevi because so much enterprise value is tied to one molecule.

14. What Is the History of Trevi Therapeutics?

Trevi Therapeutics was founded in 2011 and has been built around the development of Haduvio, its extended-release nalbuphine program. From early on, the company focused on serious symptom conditions where patients had limited good options and where a differentiated mechanism could matter clinically.

Trevi became a public company in 2019, giving it access to the equity capital needed to fund mid- and late-stage development. Earlier in its public life, the company placed meaningful emphasis on chronic pruritus and prurigo nodularis. Over time, however, chronic cough emerged as a more prominent strategic focus, especially after Trevi reported encouraging data in chronic cough associated with idiopathic pulmonary fibrosis.

The company’s history therefore reflects a common small-biotech pattern: start with a lead asset, test multiple indications, learn from the data, and then reallocate resources toward the areas that appear most likely to produce a differentiated and financeable development path. By 2024, Trevi’s identity was increasingly tied to becoming a chronic-cough-focused specialty-biopharma story built around Haduvio.

15. What Are the Key Suppliers to Trevi Therapeutics?

Suppliers matter materially to Trevi Therapeutics because it relies on external partners for much of the work needed to develop Haduvio. As with many small biopharma companies, Trevi does not publicly disclose every supplier name, but the important supplier categories are clear.

• Active pharmaceutical ingredient and excipient suppliers: Trevi needs reliable sources for nalbuphine and other inputs used in an extended-release oral formulation.
• Contract development and manufacturing organizations: these partners handle formulation work, tablet production, packaging, testing, and clinical supply.
• Contract research organizations: CROs are essential for running trials, monitoring sites, managing data, and supporting regulatory documentation.
• Central labs and specialty service providers: these vendors support sample handling, analytics, and trial-specific services.
• Clinical logistics providers: they move investigational product to trial sites and maintain supply continuity.

Supplier structure matters strategically because Trevi has little room for disruption. A delay in drug supply, quality release, or trial-services delivery can slow enrollment, defer data, and shorten effective cash runway. For a one-asset company, supplier reliability is not a procurement detail; it is a corporate-risk issue.

16. How Does the Supply Chain of Trevi Therapeutics Function?

Trevi Therapeutics’ supply chain is typical of a small outsourced drug developer, but with some nuances that matter. Haduvio is an oral extended-release product, so the supply chain is simpler than that of a cold-chain biologic, yet it remains highly quality-sensitive because formulation consistency and release characteristics are central to the product profile.

How the chain works

1. Sourcing: secure pharmaceutical ingredients and formulation components through qualified suppliers.
2. Manufacturing: use external manufacturers for formulation, tableting, packaging, stability work, and release testing.
3. Clinical distribution: move investigational product to study depots and clinical sites on the schedule required by ongoing trials.
4. Quality oversight: document batch quality, deviations, and change controls for regulatory compliance.
5. Regulatory support: maintain the chemistry, manufacturing, and controls package needed for future approval filings.

Why it matters strategically

For Trevi, supply-chain performance affects much more than cost. It affects trial continuity, regulatory credibility, and launch readiness. Because the company is small, it benefits from outsourcing, but that also raises dependence on limited suppliers, careful tech transfer, and strong quality agreements. In practical terms, Trevi needs a supply chain that is not just inexpensive, but stable enough to support pivotal development.

17. What Is the R&D Strategy of Trevi Therapeutics?

R&D is the core of Trevi Therapeutics. The company’s research and development strategy is not broad basic-science discovery; it is focused translational and clinical development around one lead asset.

Key features of the R&D strategy

• One asset, multiple indications: Trevi is trying to create multiple shots on goal from Haduvio rather than running a diversified portfolio of unrelated molecules.
• Mechanism-led indication selection: the company has targeted conditions in which neurologically mediated cough or itch may be addressed by Haduvio’s receptor profile.
• Stage-gated development: Trevi has moved from proof-of-concept work toward more advanced studies in the indications that appear most promising.
• Clinically measurable endpoints: symptom indications require strong endpoint discipline, which is why cough frequency and patient-reported symptom burden are strategically important.
• Outsourced execution, internal oversight: Trevi uses external partners for much of the heavy operational work while retaining strategic control of program design and prioritization.

Why the strategy is distinctive

Trevi’s R&D strategy is narrower and potentially more capital-efficient than that of many platform biotechs. The tradeoff is concentration risk. A single-asset strategy can look very efficient when data are positive and very fragile when data are mixed. That is why indication prioritization is such an important part of Trevi’s R&D model.

18. What Is the Finance Strategy of Trevi Therapeutics?

Trevi Therapeutics’ finance strategy is the finance strategy of a public clinical-stage biotech: preserve liquidity, fund the next major data inflection, and avoid building fixed-cost infrastructure too early.

Main elements of the finance strategy

• Equity-funded operations: with no product revenue, Trevi has historically relied on cash on hand and equity financing rather than internally generated operating cash flow.
• Lean cost structure: the company keeps its organization relatively small and outsources significant development and manufacturing work.
• Capital allocation by milestone: spending must be tied to trials, regulatory milestones, and the indications most likely to create value.
• No mature-company capital returns: dividend policy and buybacks are not the issue; runway and development funding are.

How finance supports strategy

Finance is tightly linked to corporate strategy at Trevi. A company this focused cannot afford to spend equally across every possible indication. The finance function therefore acts as a portfolio filter, forcing prioritization among RCC, IPF cough, prurigo nodularis, manufacturing readiness, and future commercial planning.

What investors should watch conceptually

For Trevi, the key financial questions are whether cash lasts long enough to reach meaningful data, whether spending is concentrated behind the most valuable programs, and whether the company can delay major commercial buildout costs until the regulatory path is clearer. In that sense, treasury management and trial timing are strategic finance decisions, not just accounting outcomes.

19. How Companies Like Trevi Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Trevi Therapeutics use Umbrex when they need that level of problem-solving capability without hiring a full consulting team and all the associated overhead. For a focused, milestone-driven biopharma company, independent consultants can be especially useful when management needs sharp analytical support on a defined strategic issue.

Representative projects Umbrex consultants could support for a company like Trevi Therapeutics include:

• Indication prioritization strategy across refractory chronic cough, IPF cough, prurigo nodularis, and adjacent symptom indications.
• U.S. market opportunity assessment for Haduvio, including epidemiology, treated-patient flow, specialist concentration, and likely launch scenarios.
• Competitive intelligence and war-gaming against P2X3 developers and off-label standards of care.
• Launch-readiness planning for a targeted specialty-commercial model, including field-force sizing and account segmentation.
• Payer access and pricing strategy, including evidence requirements, gross-to-net assumptions, and reimbursement barriers in specialist markets.
• Clinical trial enrollment acceleration and site-performance improvement for specialist patient populations.
• CMC and supply-chain risk assessment for outsourced manufacturing, limited-source suppliers, and launch-scale readiness.
• Ex-U.S. partnering strategy for licensing or commercialization alliances in markets where Trevi may not want to build direct infrastructure.
• Cross-functional program management office support for aligning clinical, regulatory, manufacturing, and commercial workstreams ahead of key milestones.
• Financing and scenario planning to help management compare development paths, spending options, and milestone-based capital needs.